ketorolac has been researched along with Lymph Node Metastasis in 2 studies
Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed)
ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.
5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This retrospective analysis suggests that intraoperative administration of ketorolac decreases the risk of breast cancer relapse compared with other analgesícs." | 3.76 | Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis. ( Berliere, M; De Kock, M; Forget, P; Legrand, C; Machiels, JP; Nussbaum, B; Vandenhende, J, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Forget, P | 1 |
| Vandenhende, J | 1 |
| Berliere, M | 1 |
| Machiels, JP | 1 |
| Nussbaum, B | 1 |
| Legrand, C | 1 |
| De Kock, M | 1 |
| Kausar, F | 1 |
| Davis, MP | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Perioperative Ketorolac in High Risk Breast Cancer Patients With and Without Inflammation. A Prospective Randomized Placebo-controlled Trial.[NCT01806259] | Phase 3 | 203 participants (Actual) | Interventional | 2013-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of death from any cause assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 93 |
| NaCl 0.9% 3mL | 105 |
2 years for the primary analysis + 3 additional years for secondary analysis (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 5 years) (NCT01806259)
Timeframe: 5 years
| Intervention | Participants (Count of Participants) |
|---|---|
| Ketorolac 30 mg | 80 |
| NaCl 0.9% 3mL | 96 |
2 other studies available for ketorolac and Lymph Node Metastasis
| Article | Year |
|---|---|
Do intraoperative analgesics influence breast cancer recurrence after mastectomy? A retrospective analysis.
Topics: Adult; Aged; Analgesics; Analgesics, Opioid; Analysis of Variance; Anti-Inflammatory Agents, Non-Ste | 2010 |
Ketorolac in neuropathic pain.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Brachial Plexus Neuropathies; Breast Neoplasms; Carcinoma, | 2006 |